This document is an investor presentation from Novo Nordisk, a global pharmaceutical company, summarizing the company’s first six months of 2024. It highlights Novo Nordisk's key business activities, including its performance in diabetes, obesity, rare diseases, and cardiovascular and emerging therapies. The presentation also discusses the company's strategic aspirations for 2025, which focus on environmental sustainability, social responsibility, and innovation. Finally, it dives into the company's financial performance and its manufacturing capacity.